Form 8-K - Current report:
SEC Accession No. 0001104659-22-033954
Filing Date
2022-03-15
Accepted
2022-03-15 16:23:54
Documents
13
Period of Report
2022-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm229241d1_8k.htm   iXBRL 8-K 28851
2 EXHIBIT 99.1 tm229241d1_ex99-1.htm EX-99.1 72055
  Complete submission text file 0001104659-22-033954.txt   283628

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apre-20220315.xsd EX-101.SCH 3024
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apre-20220315_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apre-20220315_pre.xml EX-101.PRE 22589
7 EXTRACTED XBRL INSTANCE DOCUMENT tm229241d1_8k_htm.xml XML 3645
Mailing Address 535 BOYLSTON STREET BOSTON MA 02116
Business Address 535 BOYLSTON STREET BOSTON MA 02116 6095104718
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 22741401
SIC: 2834 Pharmaceutical Preparations